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O ver the past 20 years, the incidence of heart failurehas markedly increased, and its prevalence in
patients over 65 years of age is now 10%.1 As such, it
represents one of the greatest challenges in public
health for the next century. Standard surgical proce-
dures, such as coronary artery bypass grafting, mitral
valvuloplasty, and/or valve replacement, have been
used to treat patients with advanced left ventricular dys-
function with good initial results. However, these pro-
cedures only prevent further myocardial deterioration
and do not act on the underlying disease, which is
myocardial fibrosis. At the opposite end of the spec-
trum, cardiac transplantation provides a radical therapy,
Objectives: Transplantation of fetal cardiomyocytes improves function of
infarcted myocardium but raises availability, immunologic, and ethical
issues that justify the investigation of alternate cell types, among which
skeletal myoblasts are attractive candidates.
Methods: Myocardial infarction was created in rats by means of coronary
artery ligation. One week later, the animals were reoperated on and
intramyocardially injected with culture growth medium alone (controls,
n = 15), fetal cardiomyocytes (5 × 106 cells, n = 11), or neonatal skeletal
myoblasts (5 × 106 cells, n = 16). The injections consisted of a 150-µL vol-
ume and were made in the core of the infarct, and the animals were immuno-
suppressed. Left ventricular function was assessed by echocardiography
immediately before transplantation and 1 month thereafter. Myoblast-trans-
planted hearts were then immunohistologically processed for the expression
of skeletal muscle–specific embryonic myosin heavy chain and cardiac-spe-
cific connexin 43.
Results: The left ventricular ejection fraction markedly increased in the fetal
and myoblast groups from 39.3% ± 3.9% to 45% ± 3.4% (P = .086) and from
40.4% ± 3.6% to 47.3% ± 4.4% (P = .034), respectively, whereas it
decreased in untreated animals from 40.6% ± 4% to 36.7% ± 2.7%.
Transplanted myoblasts could be identified in all animals by the positive
staining for skeletal muscle myosin. Conversely, clusters of connexin 43
were not observed on these skeletal muscle cells.
Conclusions: These results support the hypothesis that skeletal myoblasts are
as effective as fetal cardiomyocytes for improving postinfarction left ven-
tricular function. The clinical relevance of these findings is based on the pos-
sibility for skeletal myoblasts to be harvested from the patient himself.
(J Thorac Cardiovasc Surg 2000;119:1169-75)
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COMPARISON OF THE EFFECTS OF FETAL CARDIOMYOCYTE AND SKELETAL MYOBLAST 
TRANSPLANTATION ON POSTINFARCTION LEFT VENTRICULAR FUNCTION
SURGERY FOR ACQUIRED
CARDIOVASCULAR DISEASE
but organ shortage, along with strict eligibility criteria,
mandate the search for alternate treatments in cases in
which a substantial portion of the myocardium has
been irreversibly destroyed.
Among those treatments, cellular transplantation has
emerged as a possible means of increasing the number
of contractile elements in damaged myocardium. We2
and others3,4 have previously shown that fetal car-
diomyocyte transplantation improves the function of
ischemic and globally failing hearts. In a clinical per-
spective, however, the use of fetal cardiomyocytes rais-
es several issues, including availability, immunogenici-
ty, and ethics. These considerations have led to the
search for alternate cell types among which skeletal
muscle progenitors (myoblasts, also known as satellite
cells) are attractive candidates because (1) they can re-
enter the cell cycle, and thus should augment the num-
ber of contractile elements in the host myocardium, and
(2) they can be used as autografts, thereby avoiding any
immunologic conflict. The present study was therefore
designed to assess, in a rat model of coronary artery li-
gation, whether the functional benefits of intramyocar-
dially injected fetal cardiomyocytes on postinfarct
function could be equaled by skeletal myoblasts.
Material and methods
Wistar rats were used in this study. All animals received
humane care in compliance with the “Principles of Laboratory
Animal Care” formulated by the National Society for Medical
Research and the “Guide for the Care and Use of Laboratory
Animals” prepared by the National Academy of Sciences and
published by the National Institutes of Health (National
Institutes of Health Publication No. 80-23, revised 1985).
Fetal cardiomyocyte isolation procedure. Cardio-
myocytes from fetal rat hearts were isolated and purified as
previously described.2 Twenty-day-old embryos (Iffa Credo,
les Oncins, France) were removed, and their hearts were
enzymatically digested. The pellet was then resuspended in a
culture medium (68% Dulbecco’s modified Eagle medium
[DMEM], 17% medium 199, 10% horse serum, and 5% calf
serum in the presence of 100 IU/mL penicillin, 10–7 mol/L
triiodothyronine, 100 mg/mL streptomycin, and 10–9 mol/L
insulin) and diluted to achieve a final concentration of 5 × 106
cells/150 µL to be used for the intramyocardial injections.
This procedure was performed on the day of transplantation
and has previously been shown to preserve viability of cells.2
Neonatal myoblast isolation procedure. Primary muscle
cell cultures were prepared from newborn Wistar rats (Iffa
Credo). The 4 legs were skinned and dissociated enzymati-
cally at 37°C by using first collagenase IA (2 mg/mL for 1
hour; Sigma Chemical Company, St Louis, Mo) and trypsin
(0.25% for 20 minutes; Gibco BRL, Life Technologies, Inc,
Rockville, Md). The cells were grown in 57% DMEM, 27%
Earle’s 199 medium, 15% fetal calf serum, and 1% antibiotics
(all components from Gibco). The cells were harvested and
frozen on the second day. Twenty-five million cells were pre-
pared from one newborn. A homogeneous stock of cells was
prepared on the same day from 20 newborns. The cells from
this stock were used throughout the transplantation experi-
ments. On the day of transplantation, the cells were rapidly
thawed and washed 3 times in injection medium, which con-
tained 75% DMEM, 24% 199, and 0.5% bovine serum albu-
min (Fraction V, Sigma). The cell death did not exceed 5%,
as assessed by trypan blue staining. Samples of 5 × 106 cells
were prepared and kept on ice until transplantation.
After thawing, some samples were plated onto 12-well
dishes in growth medium for desmin immunolabeling.
Eighteen hours after seeding, the cells were fixed in
methanol. Nonspecific labeling was blocked by use of a mix-
ture of 5% horse serum and 5% fetal calf serum in phosphate-
buffered saline solution (PBS). The cells were incubated with
anti-desmin antibody (clone 33, 1:300, 1 hour; Dako, Trappes,
France) and then with Cy3-conjugated anti-mouse immuno-
globulin antibody (Jackson, 1:300, 1 hour; Asnières, France).
With the use of an inverted microscope, several fields were
randomly photographed both under fluorescent illumination
and phase contrast. The percentage of myogenic cells was
obtained by dividing the total number of cells counted on
phase contrast pictures by the total number of desmin-positive
cells counted on immunofluorescence pictures.
Myocardial infarction model. Male rats weighing an
average of 230 g were anesthetized with ketamine (50 mg/kg
body weight administered intraperitoneally) and xylazine (5
mg/kg body weight administered intraperitoneally) and tra-
cheally ventilated. Each heart was exposed through a lateral
thoracotomy. The left coronary artery was then identified and
occluded proximally by means of a 7-0 polypropylene snare
(Ethicon, Inc, Somerville, NJ).
Functional assessment. One week after myocardial
infarction and 1 month after cellular transplantation, cardiac
function was studied by echocardiography. Left ventricular
dimensions and function were assessed by 2-dimensional
echocardiography (Sequoia; Acuson Corp, Mountain View,
Calif) equipped with a 15-MHz phased-array linear transduc-
er (15L8), allowing a 160-Hz maximal frame rate and specif-
ically designed for cardiac ultrasonic studies in murine mod-
els. The probe was positioned on the left anterior side of the
chest after the precordium was shaved, and the rat was placed
on a warming pad. The heart was imaged in 2-dimensional
mode at a minimum depth setting and image size by means of
the RES enhanced resolution imaging function in the long-
axis view of the left ventricle, taking care to include the
mitral and aortic valves and the apex. Care was taken to avoid
excessive pressure. When a correct image was obtained with
well-defined continuous interfaces for the septum and poste-
rior wall at the higher frame rate, a numeric acquisition was
performed on the hard disk of the echocardiographic
machine. The following measurements were then performed
on-line at end-diastole (at the time of apparent maximal cav-
ity dimension) and at end-systole (at the time of maximum
anterior motion of the posterior wall) by use of the cine-loop
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feature to retrospectively obtain adequate visualization of the
following fast-beating hearts (300-400 beats/min): maximal
left ventricular long-axis lengths and endocardial area trac-
ings (by using the leading edge method). These data were
then used to calculate left ventricular end-diastolic volume
(LVEDV) and left ventricular end-systolic volume (LVESV)
by using the single-plane area-length method: EF = LVEDV
– LVESV/LVEDV, where EF is ejection fraction. All mea-
surements were made by one experienced observer who was
blinded to the treatment group. Measurements were averaged
over 3 to 5 consecutive cardiac cycles. Intraobserver variabil-
ity was assessed at baseline by 2 sets of measurements in 10
randomly selected rats, and the coefficient of correlation and
the standard error of estimate were calculated according to
the method of Bland and Altman.5
Experimental groups. One week after coronary artery li-
gation, left ventricular function was echocardiographically
assessed. Thereafter, rats (n = 42) were reoperated on through
a median sternotomy and randomly allocated to 1 of the fol-
lowing 3 groups. In the control group (n = 15) 150 µL of cul-
ture medium alone (without cells) was injected subepicar-
dially by using a 30-gauge needle in the core of the infarcted
area. The fetal group (n = 11) received an equivalent volume
supplemented with fetal cardiomyocytes (5 × 106 cells in 150
µL of culture medium) at the same time point and in the same
location. The myoblast group (n = 16) also received an equiv-
alent volume supplemented with neonatal myoblasts (5 × 106
cells in 150 µL of culture medium). Differences in the inci-
dence of deaths that occurred intraoperatively or therafter
account for the observation that sample sizes were unequal.
All animals received cyclosporine (INN: ciclosporin)
throughout the study (15 mg · kg–1 · d–1 administered
intraperitoneally; Sandoz Pharmaceutical Corporation, Basel,
Switzerland), starting 3 hours before anesthetic induction.
One month after the transplantation, left ventricular function
was assessed again by means of echocardiography.
Pathology. Twenty-four hours after the last echocardiograph-
ic study, the rats were killed by injecting an overdose of keta-
mine and xylazine. The hearts were removed and rapidly rinsed
in PBS. They were snap-frozen in isopentane cooled with nitro-
gen. Serial sections 8-µm thick were prepared by use of a cryo-
stat and subsequently processed for standard histology (hema-
toxylin-eosin staining) and immunohistofluorescence (desmin,
myosin, and connexin staining). The fate of the transplanted
myoblasts was investigated by looking for the presence of car-
diac- or skeletal-specific antigens on serial sections of heart tis-
sue. The sections were rinsed in PBS and fixed with cold
methanol for 5 minutes, and the nonspecific labeling was
blocked with a mixture of 5% horse serum and 5% fetal calf
serum in PBS for 30 minutes. The sections were incubated with
the primary antibody for 1 hour at room temperature. We used
the mouse monoclonal antibody directed against desmin (1:300,
Dako), the mouse monoclonal antibody directed against the
embryonic myosin heavy chain (EMHC; a gift of Dr Gillian
Buttler-Browne, Paris, France; dilution 1:5), and a polyclonal
rabbit anti-connexin 43 antibody (gift of Dr Daniel Gros,
Marseille, France; dilution 1:100). After several washes, the
sections were incubated with the Cy3-conjugated anti-mouse or
anti-rabbit immunoglobulin antibodies (1:200, Jackson) for 1
hour at room temperature. The sections were mounted in PBS-
glycerol (1:1).
Data analysis. For statistical analysis, we used SAS pro-
cedures (Statistical Analysis System, Cary, NC). Echocardio-
graphic data recorded in the 3 groups before and after
myocardial injections were compared by means of 1-way
analysis of variance. Within each group, echocardiographic
data were compared before and 1 month after myocardial
injections by paired t tests. Mean EFs at 1 month were com-
pared between groups after adjustment for basal EF. If analy-
sis of variance was significant, groups were compared by
using a Scheffé test. Data are given as means ± SEM.
Results
Characterization of the cell preparation. On the
day of injection, desmin immunostaining indicated that
approximately 60% of the cells were expressing this
muscle-specific marker; approximately 6000 cells were
counted.
Functional assessment. Baseline pretransplant
echocardiographic data were not different among the 3
groups (Table I). One month later, the major result is that
transplantation of either fetal cells or skeletal myoblasts
improved EF compared with control hearts (Table I).
This was paralleled by a significant increase in LVEDV
in control rats (from 0.46 ± 0.02 at baseline to 0.68 ±
0.04 at 1 month, P = .0007), whereas remodeling was
limited in the transplanted hearts with LVEDV, being
0.45 ± 0.03 at baseline and 0.58 ± 0.06 at 1 month (P =
.038) in the fetal group and 0.52 ± 0.04 at baseline and
0.6 ± 0.05 at 1 month (P = .11) in the myoblast group.
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Table I. Two-dimensional EF measurements
Control (n = 15) Fetal (n = 11) Myoblast (n = 16)
Left ventricular EF
Baseline (EF1) 40.6% ± 4.0% 39.3% ± 3.9% 40.4% ± 3.6%
One month (EF2) 36.7% ± 2.7% 45.0% ± 3.4% 47.3% ± 4.4%
∆ EF (EF2–EF1) –4.0% ± 11.2% 5.64% ± 12.9% 6.94% ± 13.9%
P value (vs baseline) .19 .086 .034
The baseline between-group difference was a P value of .97. All data are given as means ± SEM.
Comparison of EF at 1 month between groups
demonstrated a clear effect of transplantation (P =
.09); these differences were even more marked after
adjustment on baseline EF (P = .0001), with EF in
myoblast and fetal groups greater than that found in
control animals (P < .05 [confidence limits = 0.45-
21.0] and P > .05 [confidence limits = 2.9-19.7],
respectively), but without significant differences
between the 2 transplanted groups. The salutary
effects of cellular transplantation were further sup-
ported by the scattergram (Fig 1) plotting 1-month
functional outcome versus baseline data. Thus hearts
with the largest infarcts and the greatest impairment
of EF (baseline values of <40%) were found to bene-
fit most from the transplantation procedure. However,
even in cases where the impairment of baseline EF
was less pronounced (>40%), the beneficial effects of
cellular transplantation were still apparent, as reflect-
ed by a stability of EF over time, which contrasted
with the marked alterations of this parameters in con-
trol hearts (Fig 1). Of note, these post-transplantation
functional data were recorded under similar condi-
tions of heart rate (300 ± 19 beats/min, 293 ± 15
beats/min, and 308 ± 22 beats/min in the control,
fetal, and myoblast groups, respectively).
Histologic characterization of the transplanted
tissue. Multinuclear elongated structures were
observed within the injected area 4 weeks after trans-
plantation (Fig 2, A). These structures were seen both
in the core and at the borders of the infarcted area, and
they were absent from hearts that did not receive the
skeletal muscle cells. Immunostaining for EMHC
revealed both small and elongated cells in the infarcted
zone of the rats injected with the primary cultures (Fig
2, B). These structures were typical of myotubes and
muscle fibers, and they were aligned along either the
long or the short axis of the heart. The smallest stained
cells were probably committed myoblasts. Desmin
staining of serial sections confirmed the muscular
nature of the structures for EMHC (Fig 2, C). Desmin
staining also revealed the presence of cardiac tissue
surrounding the skeletal tissue at the borders of the
infarcted zone; this cardiac tissue did not express
EMHC. Finally, connexin 43 was expressed by the car-
diac cells surrounding the skeletal muscle; however,
the myoblasts, myotubes, and skeletal muscle fibers
did not express connexin 43 (Fig 2, D). In summary,
engrafted myoblasts were identified within and at the
borders of the fibrous scar by their positive staining for
desmin and EMHC (a specific marker of skeletal
myoblasts) and could thus be differentiated from the
surrounding host cardiomyocytes, which only stained
for desmin (a nonspecific marker of muscular cells).
Discussion
The two major findings of this study are that (1)
transplantation of fetal cardiomyocytes improves func-
tion of infarcted myocardium, primarily through a
reduction of left ventricular remodeling, and (2) this
functional benefit can be matched by intramyocardial
injection of skeletal myoblasts.
Echocardiographic assessment of function. Be-
cause rat hearts beat at a fast rate and because of the
limitation of M-mode echocardiography in assessing
volumes and performance in infarcted ventricles, we
used a 2-dimensional echocardiographic machine,
allowing a numeric acquisition of a maximum of 160
images per second and yielding more than 25 heart
scans at a heart rate of 300 beats/min. Previous necrop-
sy findings have shown that the left ventricle in rats has
an elliptical shape, which justifies that volume mea-
surements were based on an elliptical model of left
ventricular geometry.6 We used the single-plane area-
length method, which has been shown in human
infarcted hearts to be more accurate than those relying
on M-mode measurements. The echocardiographic
method of volume calculation was based on a single
plane model, which could underestimate the extent of
infarction. This method was preferred to biplane meth-
ods, which have not yet been validated in infarcted rats
and are difficult to apply in practice because of cavity
distortion after large anterior infarction. Thus in this
study differences between groups might have only been
underestimated.
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Fig 1. Two-dimensional echocardiographic EF of each group
before and 1 month after transplantation.
Fetal cardiomyocyte transplantation. The func-
tional benefits of fetal cell transplantation have been
well established in myocardial infarction models creat-
ed by cryonecrosis3 or coronary artery ligation2 and in
which function was assessed by in vitro Langendorff
perfusion studies3 or in vivo echocardiographic mea-
surements.2 More recently, these observations made in
regionally ischemic preparations have been extended to
the setting of global heart failure induced by anthracy-
clines.4 The present data extend these findings mecha-
nistically.
Namely, the fact that intramyocardially injected fetal
cardiomyocytes primarily limited left ventricular dila-
tion strongly suggests that the elastic properties of
these cells played a major role in the overall improve-
ment of function.7 Indeed, this improvement was prob-
ably underestimated because of the expectedly limited
effects of cell transplantation in rats with initially small
infarcts that did not tend to substantially enlarge over
time. Conversely, the greatest benefits were seen in
those animals with the largest infarcts and the conse-
quently lowest pretransplant EFs, which supports the
potential relevance of this procedure to patients with
severe ischemic cardiomyopathy. However, apart from
limitation of remodeling, other mechanisms could
account for the functional benefits of fetal cardiomyo-
cyte transplantation. For example, these cells have been
shown to establish gap junctions with those of the
recipient myocardium,8 which should allow them to
beat synchronously with adjacent cells and thus direct-
ly contribute to enhanced contractility. Indeed, analysis
of our data in relation with the pretransplant functional
status of hearts raises the possibility that a contention
mechanism could prevail in cases of initially small
infarcts, whereas direct systolic assistance would be
additionally involved in large infarcts. It is also con-
ceivable that intracardiac grafts could act as platforms
releasing growth factors, angiogenic factors, or both.
This hypothesis is indeed supported by two lines of evi-
dence: (1) intramyocardially implanted cardiomyo-
cytes increase the density of capillaries and arterioles9
and (2) locally injected cells improve global heart func-
tion, although they do not seem to migrate away from
the implant sites,10,11 which could be consistent with
paracrine effects exerted by cell-derived mediators.
A major issue raised by fetal cardiomyocyte trans-
plantation is tracing of the injected cells within the host
myocardium. This is due to the fact that fetal car-
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Fig 2. Photomicrographs of skeletal muscle tissue 4 weeks after transplantation into the myocardial scar. A,
Elongated multinucleated fibers (asterisks) are formed within the scar tissue. These fibers contain central nuclei
(arrows; hematoxylin and eosin staining). Panels B, C, and D show serial sections of immunohistofluorescence
staining. B, A cluster of skeletal muscle fibers (asterisk) surrounded by small myotubes characterized by embry-
onic myosin heavy chain staining. C, The same cluster of skeletal muscle fibers (asterisk) and also the surround-
ing host cardiac tissue (arrows) are positive for desmin staining. D, The surrounding host cardiac tissue (arrow),
but not the skeletal muscle fibers (asterisk), stain positively for connexin 43. (Original magnification ×150.)
diomyocytes lose their characteristic phenotypic pat-
terns over time and become progressively indistin-
guishable from adult host cardiomyocytes. The
intramyocardial injections of genetically labeled cells
expressing β-galactosidase activity has been the most
common means of identifying them once they have
been engrafted into the recipient heart. However,
despite immunossupressive therapy, the expression of
β-galactosidase can be highly immunogenic12 and,
through this mechanism, can adversely affect function.
Thus to avoid confounding of our echocardiographic
measurements by this factor, we made no attempt to
label injected fetal cells, assuming that we2 and oth-
ers8,7,3 have previously documented their ability to
form stable intracardiac grafts.
Skeletal myoblast transplantation. Myoblasts feature
several advantages for cellular transplantation, including
their capacity to proliferate. Neonatal myoblasts have
thus been shown to replicate in the recipient myocardium
until 1 week after grafting.11 Furthermore, although most
engrafted myoblasts differentiate into mature fibers,
some of them might become quiescent established satel-
lite cells that could participate in tissue repair in cases of
subsequent ischemic episodes.11
Our data confirm that neonatal skeletal myoblasts can
be successfully engrafted in ischemically damaged
myocardium, can limit infarct expansion, and can
improve 1-month EF compared with values recorded
before transplantation, as well as those yielded by non-
transplanted control animals at a time-matched study
point (ie, 1 month after injection of the culture medium
alone). In the present study neonatal myoblasts were used
to enhance the efficacy of in vitro expansion before
implantation. Furthermore, grafting allogenic cells also
provided the opportunity to provide cyclosporine
immunossupression under the same conditions as those
used in the fetal cardiomyocyte transplantation experi-
ments. This was deemed methodologically important to
avoid between-group comparisons of functional outcome
to be confounded by the intrinsic effects of cyclosporine
on postinfarct myocyte hypertrophy.13 However, in a rab-
bit model of cryonecrosis, Taylor and associates14 have
shown that injections of autologous adult myoblasts were
equally successful in improving systolic and diastolic
function, as assessed by ultrasonic dimension transduc-
ers. In this study a causal relationship between the pres-
ence of myoblasts and outcome was clearly established in
that function was only found to improve in hearts that
were successfully engrafted.
The mechanism by which skeletal myoblast trans-
plantation is functionally beneficial remains elusive.
Chiu and coworkers15 have hypothesized that implant-
ed satellite cells can undergo a milieu-induced differ-
entiation that leads them to acquire a cardiac-like phe-
notype. This hypothesis is largely based on the obser-
vation by these authors15 and others14 of structures
resembling intercalated disks between transplanted
myoblasts. The influence of the cardiac environment
on the phenotypic changes of engrafted cells is further
suggested by their conversion to fatigue-resistant slow-
twitch fibers.11,16 However, implanted myoblasts fail to
express cardiac-specific myosin heavy chain up to 3
months after transplantation.11 The formation of inter-
caleted disks between cardiac host cells and donor cells
labeled with a reporter gene has been unambiguously
reported only in the case in which a permanent mouse
myogenic cell line (C2C12) was injected into a nonin-
farcted mouse myocardium.17 Our present results argue
against a classical pathway of electrical coupling of
cardiac and skeletal tissue in vivo because engrafted
myoblasts, identified within and around the fibrotic tis-
sue by their positive staining for the skeletal
muscle–specific myosin heavy chain, failed to express
connexin 43 on their sarcolemma. Taken together, these
data suggest that some structures may develop over
time that mechanically tether implanted myoblasts to
the adjacent host cardiomyocytes. Conversely, gap
junction–supported electrical coupling, which is a pre-
requisite for transplanted cells to provide synchronized
mechanical support, is more unlikely to occur.
Interestingly, the present results show that the lack of
such a coupling did not preclude improvement of
postinfarct function of myoblast-implanted hearts to
the same extent as hearts transplanted with fetal car-
diomyocytes. Likewise, the functional benefits of
skeletal myoblasts14 and fetal cardiomyocytes3 have
been reported in cryoinjury models in which implanted
cells are insulated from the remaining myocardium by
scar tissue and have therefore no possibility for estab-
lishing connections with host cardiomyocytes. This
suggests that skeletal myoblasts could primarily be car-
dioprotective through their elastic properties, which
would oppose the trend for postinfarct fibrous tissue to
dilate over time. Because skeletal muscle tissue is
formed both in the core and at the borders of the
infarcted zone, cardiac, fibrotic, and skeletal tissues are
intricated in vivo. The production of a muscle tissue of
skeletal nature within the infarcted area, however, may
change the physical properties of the scar and lead to a
better compliance of the cardiac tissue, which could
become more resistant to a progressive dilation. Thus
transplanted cells would act as a tissue bandaging with-
in the scar tissue. This hypothesis, which is consistent
with our observations of limited remodeling in
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myoblast-implanted hearts, is also supported by the
micromanometric and sonomicrometric findings that
these cells are particularly effective in preserving
postinfarct diastolic compliance.18
In conclusion, transplantation of skeletal myoblasts
limits postinfarct remodeling of the left ventricle and
ultimately results in improved function. This improve-
ment was similar in magnitude to that seen after
implantation of fetal cardiomyocytes. Because skeletal
myoblast transplantation would be easier to implement
in clinical practice, it might thus find a place in the
armamentarium of techniques designed to augment
function of the failing heart.
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Discussion
Dr Bradley S. Allen (Oak Lawn, Ill). I have a question
from a clinical standpoint. It seems that what you have done
is just thickened the scar so that the ventricle does not dilate.
Clinically, most of our cardiologists seem to do the same
thing just by opening up the artery at the end of an infarct
either with tissue plasminogen activator or angioplasty. Do
you have a group in which you simply opened up the artery
after the infarct, and did you see the same results as when you
transplanted cells, which seems much more complicated? 
Dr Scorsin. I did it before and, indeed, transplantation of
cells results in an improvement of function, irrespective of
whether the artery is reperfused or not.
Dr Juan C. Chachques (Paris, France). In the last 3 years
of our work on an experimental model, we have implanted
satellite cells (myoblasts) in small and big animals. We
learned that mainly in the rat model it is necessary to corre-
late the echocardiographic studies with histologic studies
because in many cases we do not find cells in the myocardi-
um, even with an improvement in EF. Therefore I recommend
that you correlate all your research in small animals with his-
tologic studies of the myocardium because you can improve
the EF by another mechanism that is not related to cell
implantation. I think that the main conclusions in cellular car-
diomyoplasty can be obtained by using big animals.
Dr Scorsin. Thank you for your remarks, Dr Chachques.
Dr Philippe Menasché (Paris, France). I would like to fol-
low up briefly on Dr Allen’s question. Indeed, the first study
that we did, now 5 years ago, was a study with ischemia and
reperfusion. At that time, this was actually the first study we
had done in showing that transplantation of cells did improve
function to the same extent as it did in this particular study,
where there was no reperfusion.
Regarding Dr Chachques’ comments, it should be noted
that in all these animals, the improvement in function
assessed by echocardiography was actually correlated with
the presence of engrafted cells, which could be identified in
all animals. This has also been shown by Doris Taylor by
using a slightly different rabbit model, which shows a close
correlation between engraftment of cells and improvement of
function. Therefore we definitely believe that even if the
mechanism by which cells improve function remains elusive,
there is a clear correlation between the fact that cells are pres-
ent in the tissue and the fact that function is improved.
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